FINWIRES · TerminalLIVE
FINWIRES

$COSM

18 stories mentioning COSMUpdated 2d ago

Every FINWIRES story that references COSM, newest first.

What's the latest news on COSM?

Sectors

Sector Update: Healthcare Stocks Decline Late Afternoon

Healthcare stocks were lower late Friday afternoon, with the NYSE Healthcare Index down 0.3% and the State Street Health Care Select Sector SPDR ETF (XLV) easing 0.1%.The iShares Biotechnology ETF (IBB) rose 0.5%.In corporate news, Novo Nordisk (NVO) shares fell 2% after Morgan Stanley downgraded the stock to underweight from equal weight.Eli Lilly (LLY) said Friday that it has completed its acquisition of AtaiBeckley (ATAI), a clinical-stage biopharmaceutical company developing rapid-acting neuroplastogens for mental health conditions. Lilly shares were down 0.6%.Cosmos Health (COSM) said Friday its unit Cana Laboratories entered a new five-year contract manufacturing deal with Viofar to secure 2.5 million additional units of the Rosartia cardiovascular medicine. Cosmos shares rose 1.2%.Exelixis (EXEL) shares fell 1.5% after it said the US Food and Drug Administration extended the review period for its new drug application for its metastatic colorectal cancer candidate zanzalintinib, in combination with atezolizumab, by three months.

$COSM$EXEL$LLY$NVO
Sectors

Sector Update: Healthcare Stocks Ease in Afternoon Trading

Healthcare stocks were edging down Friday afternoon, with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF (XLV) each fractionally lower.The iShares Biotechnology ETF (IBB) rose 0.5%.In corporate news, Eli Lilly (LLY) said Friday that it has completed its acquisition of AtaiBeckley (ATAI), a clinical-stage biopharmaceutical company developing rapid-acting neuroplastogens for mental health conditions. Lilly shares were slightly lower.Cosmos Health (COSM) said Friday its unit Cana Laboratories entered a new five-year contract manufacturing deal with Viofar to secure 2.5 million additional units of the Rosartia cardiovascular medicine. Cosmos shares gained 5%.Exelixis (EXEL) shares fell 1.7% after it said the US Food and Drug Administration extended the review period for its new drug application for its metastatic colorectal cancer candidate zanzalintinib, in combination with atezolizumab, by three months.

$COSM$EXEL$LLY
Sectors

Sector Update: Healthcare

Healthcare stocks were lower Friday afternoon, with the NYSE Healthcare Index easing 0.1% and the State Street Health Care Select Sector SPDR ETF (XLV) fractionally lower.The iShares Biotechnology ETF (IBB) rose 0.3%.In corporate news, Cosmos Health (COSM) said Friday its unit Cana Laboratories entered a new five-year contract manufacturing deal with Viofar to secure 2.5 million additional units of the Rosartia cardiovascular medicine. Cosmos shares gained 4.2%.

$COSM
Wire

Cosmos Health Unit Enters 5-Year Contract Manufacturing Deal With Viofar Over Cardiovascular Medicine

Cosmos Health (COSM) said Friday its unit Cana Laboratories entered a new five-year contract manufacturing deal with Viofar to secure 2.5 million additional units of the Rosartia cardiovascular medicine.Under the five-year deal, Cana will manufacture 500,000 units of the medicine annually, across the 5mg, 10mg, 20mg and 40mg dosages.The new agreement ramps Cana's cumulative contract manufacturing orderbook to over 27.5 million units, and provides greater visibility into future production volumes and related cash flows, the company said.Price: $0.27, Change: $+0.02, Percent Change: +6.36%

$COSM
Wire

Cosmos Health, Libytec Enter Distribution Deal for Diabetes Drug

Cosmos Health (COSM) said Monday it has entered into a distribution and promotion deal with Libytec Pharmaceutical for its type-2 diabetes medication DIABIT-IS X in Greece.The company said its Cana Laboratories unit will provide the supply, while Libytec will manage distribution, medical information and promotional activities across Greece.The five-year arrangement is projected to lift revenue and cash flow while positioning the business to introduce the product in additional European markets, the company added.The medicine, which contains the active substance sitagliptin, is a generic version of Merck's (MRK) Januvia, Cosmos Health said.Shares of the company were up 8.3% in Monday trading.Price: $0.32, Change: $+0.02, Percent Change: +8.27%

$COSM$MRK
Sectors

Sector Update: Healthcare Stocks Decline Late Afternoon

Healthcare stocks were lower late Friday afternoon, with the NYSE Healthcare Index decreasing 0.7% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 0.8%.The iShares Biotechnology ETF (IBB) fell 2.6%.In corporate news, Bausch + Lomb (BLCO) shares fell 2.9%. The company said late Thursday that results from a phase 2 trial assessing BL1107 in people with glaucoma showed the study did not meet its primary endpoint of replicating visual function improvements seen in a smaller phase 1/2a trial.Pfizer's (PFE) Q2 revenue is expected to match Wall Street's estimates, but its EPS may fall short, RBC said in a note. Separately, Pfizer's vaccine disputes with Poland and Romania continue, now extending to the countries' air traffic agencies, Bloomberg reported. Pfizer shares were fractionally higher.SL Science (SLBT) shares gained 4.4% after it said Friday it has submitted an orphan drug designation request to the US Food and Drug Administration for its Gamma Delta T therapy, named Vdelta2+ Gamma Delta T Cells, for the treatment of glioblastoma multiforme.Cosmos Health (COSM) shares jumped 15% after it said Friday that it has launched a subscription-based purchasing model for its consumer health brands.

$BLCO$COSM$PFE$SLBT
Wire

Sector Update: Healthcare Stocks Decline Friday Afternoon

Healthcare stocks were lower Friday afternoon, with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF (XLV) each shedding about 1%.The iShares Biotechnology ETF (IBB) fell 2.7%.In corporate news, Bausch + Lomb (BLCO) shares fell 3.5%. The company said late Thursday that results from a phase 2 trial assessing BL1107 in people with glaucoma showed the study did not meet its primary endpoint of replicating visual function improvements seen in a smaller phase 1/2a trial.Pfizer's (PFE) Q2 revenue is expected to match Wall Street's estimates, but its EPS may fall short, RBC said in a note. Separately, Pfizer's (PFE) vaccine disputes with Poland and Romania continue, now extending to the countries' air traffic agencies, Bloomberg reported. Pfizer shares were up 0.1%.Cosmos Health (COSM) shares jumped 10% after it said Friday that it has launched a subscription-based purchasing model for its consumer health brands.

$BLCO$COSM$PFE
Wire

Cosmos Health Launches Subscription-Based Purchasing Model

Cosmos Health (COSM) said Friday that it has launched a subscription-based purchasing model for its consumer health brands.The company said it has launched the subscription model for NOOR Collagen skin and joint health product in the US.Cosmos said that it plans to extend the subscription model to a broader range of its products, with further initiatives currently underway.Price: $0.27, Change: $+0.01, Percent Change: +2.60%

$COSM
Wire

Cosmos Health Expands Share Buyback to 3.4 Million Shares

Cosmos Health (COSM) said Thursday it repurchased an additional 770,000 common shares at an average price of about $0.1956 each, bringing total repurchases under its existing buyback program to 3.42 million shares.The company said it will continue to make open-market purchases under the program, which expires on Dec. 31.Price: $0.24, Change: $+0.04, Percent Change: +18.80%

$COSM
Wire

Cosmos Health Signs Qatar Distribution Deal With IMC

Cosmos Health (COSM) said Friday it signed a distribution agreement with International Medical Company, or IMC, to expand its Sky Premium Life line of nutraceuticals and food supplements into Qatar, with IMC placing an initial purchase order of 31,000 units.IMC will handle sales and marketing, regulatory affairs, logistics, and distribution in the territory, the company said.The deal is part of Cosmos Health's broader push into Gulf markets with the Sky Premium Life brand, according to the company.Price: $0.17, Change: $-0.02, Percent Change: -8.09%

$COSM
Wire

Cosmos Health to Deploy AI-Powered Call Center at Pharma Distribution Unit

Cosmos Health (COSM) said Tuesday its pharmaceutical distribution subsidiary CosmoFarm will deploy an artificial intelligence-powered call center to support customer communications, order intake and routine support functions.The platform will include multilingual voice assistance, intelligent call routing, outbound campaign automation, back-end system integration and real-time reporting capabilities, the company said.

$COSM
Wire

Cosmos Health Gets New Contract Manufacturing Orders for 253,657 Units Across Multiple Medicines

Cosmos Health (COSM) said Friday its wholly-owned subsidiary Cana Laboratories has received new contract manufacturing orders from Nassington and Verisfield.The orders comprise a combined 253,657 units covering a range of medicines and pharmaceutical products, according to a statement.Price: $0.21, Change: $+0.01, Percent Change: +2.91%

$COSM
Wire

Cosmos Health Signs Letter of Intent to Buy Doc Pharma

Cosmos Health (COSM) said late Thursday it has signed a non-binding letter of intent to acquire Doc Pharma, a fully licensed GMP pharmaceutical manufacturer.The proposed acquisition is part of its plan to build an end-to-end healthcare platform, the company said.Doc Pharma has an asset base of about $24 million and generated some $6.7 million in three-year average annual revenue, it added.Price: $0.21, Change: $-0.02, Percent Change: -10.00%

$COSM
Wire

Cosmos Health Unit Signs 3-Year Manufacturing Deal With Verisfield

Cosmos Health's (COSM) Cana Laboratories signed a three-year contract manufacturing agreement with Verisfield for 3.9 million units of VASCLOR GEST progesterone pessaries.The deal adds a new customer and expands Cana's women's-health manufacturing portfolio. Cosmos said Wednesday in a statement.Financial terms weren't disclosed.Price: $0.23, Change: $+0.01, Percent Change: +2.87%

$COSM
Wire

Cosmos Health Unit Acquires Patent Application From Cloudpharm

Cosmos Health (COSM) said its Cana Laboratories unit acquired an international patent application from Cloudpharm and has begun seeking national and regional protection in key markets.The technology combines early-stage discovery methods with advanced pharmaceutical development approaches, the company said Monday in a statement.Cana also plans to expand investment in nanotechnology-based platforms for pharmaceutical, nutraceutical, over-the-counter and specialized healthcare products.The company said the project will integrate the newly acquired IP with Cana's European manufacturing capabilities.Price: $0.22, Change: $-0.03, Percent Change: -10.53%

$COSM
Wire

Cosmos Health Completes Phase 1 Execution of Liv18 Ahead of Schedule

Cosmos Health (COSM) said Monday that it has completed the first phase execution of its Liv18 liver health supplement ahead of schedule.Production of Liv18 is expected to commence this month, with initial market rollout to follow shortly thereafter, the company said.Cosmos said that based on planned investments in advertising, customer acquisition, and business development, along with early US commercial traction from its other products, Liv18 is expected to generate over $5 million in annual revenue, with gross margins of about 75%.Shares of the company were down more than 6% in Monday's trading.Price: $0.38, Change: $-0.03, Percent Change: -6.47%

$COSM
Wire

Cosmos Health to Launch Cur18 Curcumin Supplement in US in Q2

Cosmos Health (COSM) said Friday it will launch its Cur18 curcumin supplement in the US market during Q2.The supplement is designed to overcome "poor bioavailability," a common issue with conventional curcumin formulations that do not dissolve easily in the digestive system, the healthcare company said.Cur18 uses a whole-spectrum extract that offers 39 times higher bioavailability than standard 95% curcuminoid extracts, based on a pharmacokinetic study, the company said.The study also showed that the formulation achieves 49.5 times higher total curcumin exposure, while separate clinical data showed meaningful improvements in knee pain for osteoarthritis patients, the company added.Price: $0.39, Change: $-0.02, Percent Change: -3.94%

$COSM
Wire

Cosmos Health Gets New 60,000-Unit Sky Premium Life Order From Pharmalink

Cosmos Health (COSM) received a new purchase order for 60,000 units of its Sky Premium Life products from Pharmalink under their exclusive distribution agreement for the United Arab Emirates market.This is the third straight order from Pharmalink, bringing cumulative orders since June 2024 to 270,000 units, Cosmos Health said Monday in a statement.Price: $0.31, Change: $+0.02, Percent Change: +6.14%

$COSM

Track with the FINWIRES app suite

FolioX
FolioX
Track COSM in your portfolio
WheelAI
WheelAI
Analyze COSM options with the wheel strategy
StockInsider
StockInsider
See market sentiment on COSM